Alexion Pharmaceuticals Inc.
352 Knotter Drive
About Alexion Pharmaceuticals Inc.Alexion Pharmaceuticals, Inc., is a global biopharmaceutical company focused on developing life-transforming therapies for patients with severe and life-threatening diseases that are also ultra-rare and have no effective treatment options.
Our first marketed product, Soliris® (eculizumab), is the world’s first and only approved terminal complement inhibitor. Soliris is approved in more than 40 countries as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), and in the United States, European Union and Canada as a treatment for patients with atypical hemolytic uremic syndrome (aHUS). Both PNH and aHUS are life-threatening, ultra-rare diseases that are caused by chronic uncontrolled complement activation.
Alexion currently has nine lead development programs with Soliris and four other highly innovative therapeutic candidates for patients with life-threatening and ultra-rare disorders beyond PNH and aHUS. These include, asfotase alfa as a treatment for patients with hypophosphatasia and cPMP replacement therapy for newborns with molybdenum cofactor deficiency Type A. Please click here to see our entire pipeline.
Alexion was established in New Haven, Conn. in 1992 and became a public company in 1996 (NASDAQ: ALXN). In recent years, Alexion was added to the NASDAQ-100 Index (2011) and to the Standard & Poor’s 500 Index (2012).
Headquartered in Cheshire, Conn., Alexion employs more than 1,500 people around the world. In addition to our global headquarters, Alexion's facilities include a manufacturing plant in Smithfield, R.I., a translational medicine facility in Cambridge, Mass., EMEA (Europe, Middle East & Africa) region headquarters in Lausanne, Switzerland, a European shared service center in Paris, distribution and sales operations in major markets throughout Europe, and new operations in Sydney, São Paulo, Ontario and Tokyo. The company is also expanding its reach in Latin America, the Middle East and Africa. Alexion plans to move its global headquarters back to New Haven, Conn. in 2015.
687 articles with Alexion Pharmaceuticals Inc.
Alexion Announces Upcoming Data Presentations at 72nd Annual Meeting of the American Academy of Neurology
Nine abstracts accepted, including long-term data and subgroup analyses from the Phase 3 PREVENT clinical trial evaluating SOLIRIS® (eculizumab) for the treatment of neuromyelitis optica spectrum disorder (NMOSD)
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the launch of the Alexion Charitable Foundation to provide further support for the rare disease community and for local communities which the company serves.
Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the Cowen Health Care Conference in Boston, MA on Tuesday, March 3rd, 2020 at 9:20 a.m. ET.
The company has abandoned the project based on unfavorable early-stage data.
Alexion Pharmaceuticals announced that management will present at the SVB Leerink Global Healthcare Conference in New York, NY on Tuesday, February 25th, 2020 at 9:30 a.m. ET.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the fourth quarter and full year of 2019.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced it has completed its acquisition of Achillion Pharmaceuticals, Inc. The acquisition adds two clinical-stage oral small molecule Factor D inhibitors to Alexion’s pipeline and provides the foundation and expertise for a broader oral Factor D inhibition development platform with the potential to treat numerous additional complement-mediated diseases.
UPDATED TIME: Alexion Fourth Quarter and Full Year 2019 Results Conference Call at 7:30am ET on Thursday, January 30, 2020
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that it has updated the time of its fourth quarter and full year 2019 earnings call on January 30, 2020 to 7:30 a.m. Eastern Time.
1/20/2020There were plenty of clinical trial announcements this week. Here's a look.
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2019 before the US financial markets open on January 30, 2020
The company’s chief executive officer, Ludwig Hantson, admits it's a longshot.
50-week global study to enroll ~350 patients across broad ALS population
It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.
1/13/2020The first full business week of the new year began with plenty of clinical trial news. Here’s a look.
1/10/2020The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019.
Apellis Pharmaceuticals announced that its pegcetacoplan beat out Alexion Pharmaceuticals’ Soliris in its Phase III PEGASUS study in adults with paroxysmal nocturnal hemoglobinuria.
Alexion Pharmaceuticals announced that management will present at the 38th Annual J.P Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 14th, 2019 at 7:30 a.m, PT. A breakout question and answer session will immediately follow the formal presentation.
Alexion and Achillion have not yet submitted their filings under the HSR Act, and currently anticipate doing so in January 2020.
Alexion Exercises Option for Two Additional GalXC™ RNAi Programs for Complement-Mediated Targets Under Collaboration With Dicerna™
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Dicerna™ Pharmaceuticals, Inc. (NASDAQ:DRNA) today announced that Alexion has exercised its option for exclusive rights to two additional targets within the complement pathway for the discovery and development of GalXC™ RNAi molecules.
Elliott confirms that it has had a multiyear, constructive and private engagement with Alexion that has led to value-creative changes at the Company.